Article Sidebar
Published:
Aug 10, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Oxobedfordia acid reduces colon cancer cell viability through apoptosis induction and inhibits colon cancer growth in mice model
Abstract
Purpose: Colon cancer is amongst the most commonly diagnosed carcinoma globally and ranks 3rd highest of all the kinds of tumors. In the present study effect of oxobedfordia acid on colon cancer cell viability and colorectal tumor growth in vivo was investigated.
Methods: Cytotoxicity of oxobedfordia acid in SW480, HCT116, and FHC cells was evaluated by MTT assay. Colon cancer in the mice was induced by implanting subcutaneously 2 x 106 HT-29 cells/mouse in the right flank. Various parameters, including cell viability, tumor growth and expression levels of cancer factors, were also assessed.
Results: Treatment with oxobedfordia acid significantly reduced viability in SW480 and HCT116 cells (p < 0.05). Furthermore, oxobedfordia acid caused increased miR-331-3p levels in cells. Moreover, oxobedfordia acid caused a significant reduction in NRP2 expression and increased apoptosis induction in SW480 and HCT116 cells. Oxobedfordia acid treatment for 48 h significantly increased p53 and p-c- Jun levels, but reduced Bcl-2 expression in cells (p < 0.05). In the mouse model of colon cancer, oxobedfordia acid significantly retarded tumor growth. Furthermore, in oxobedfordia acid-treated mice, expression of miR-331-3p was elevated while NRP2 level was lowered when compared with control group (p < 0.05).
Conclusion: Oxobedfordia acid treatment suppresses colon cancer cell viability and inhibits tumor growth in mice through enhancement of miR-331-3p and reduction in NRP2 expression. Hence, oxobedfordia acid can potentially be developed as an agent for the management of colorectal cancer.
